Results for: Quiz 1z0-076 - Oracle Database 19c: Data Guard Administration Marvelous Reliable Exam Sample 🔡 Download ▷ 1z0-076 ◁ for free by simply searching on “ www.pdfvce.com ” 😙1z0-076 Valid Test Tips

Increased cardiovascular risk in Parkinson’s disease

December 16, 2015

…ts and 3,211 propensity score-matched subjects without PD. During the three-year follow-up, there were 83 fatal or non-fatal AMIs in the PD group compared to 53 in the non-PD group (hazard ratio 1.67). There were also significant differences in the PD versus non-PD groups for the combined endpoint of AMI or cardiovascular death (HR 1.46), and for AMI or all-cause mortality (HR 1.42). A separate study also reported an increased risk of ischemic str…

High-efficacy MAbs in MS: an update

November 25, 2015

…SS worsening was higher in patients with relapses compared to those relapse-free (23.6% vs. 15.0%), suggesting that early EDSS worsening is largely attributable to relapse-related deficits. This contrasts with the findings in secondary-progressive MS (SPMS): in the recently reported ASCEND trial of natalizumab, treatment was ineffective in slowing disability unrelated to relapses (www.businesswire.com/news/home/20151021005273/en/Biogen-Reports-Top…

Depression in PD often untreated despite improved detection

November 18, 2015

…all, 23% of patients had clinically significant symptoms of depression (PDQ-39e >10). One-third were taking antidepressants, 6% were using mental health services and 14% were using both; 47% remained untreated. Patients with untreated depression tended to be older, with a shorter duration of PD, living at home, and with a spouse/partner as the regular care partner. During the one-year observation period, 9.3% of patients with depression started tr…

New data on first-line oral therapies in MS

November 4, 2015

…l. ECTRIMS 2015; abstract P1031). Overall, 87% of patients who were relapse-free had no disability worsening. For the 22% of patients with confirmed disability progression, 84.5% experienced worsening disability within 30 days after experiencing a relapse, suggesting that short-term disability is largely attributable to relapse-related residual deficits. The two phase III studies of teriflunomide demonstrated a consistent effect of treatment on di…

Late-breaking news at ECTRIMS 2015: ocrelizumab, minocycline and biotin

October 28, 2015

…review of CIS trials see Freedman et al. Mult Scler Relat Disord 2014;3:147-155; free full text at www.msard-journal.com/article/S2211-0348(13)00085-0/pdf). A pilot study of minocycline in MS (Zhang et al. Can J Neurol Sci 2008;35:185-191), and as add-on therapy to glatiramer acetate (Metz et al. Mult Scler 2009;15:1183-1194) have previously reported some benefits with the antibiotic, most notably in reducing inflammatory activity on MRI. Biotin i…